Stock Analysis
Waverley Pharma Full Year 2023 Earnings: CA$0.041 loss per share (vs CA$0.012 loss in FY 2022)
Waverley Pharma (CVE:WAVE) Full Year 2023 Results
Key Financial Results
- Revenue: CA$412.1k (down 67% from FY 2022).
- Net loss: CA$2.22m (loss widened by 235% from FY 2022).
- CA$0.041 loss per share (further deteriorated from CA$0.012 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Waverley Pharma's share price is broadly unchanged from a week ago.
Risk Analysis
You still need to take note of risks, for example - Waverley Pharma has 5 warning signs we think you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Waverley Pharma is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSXV:WAVE
Waverley Pharma
A biopharmaceutical company, researches, develops, and commercializes cancer therapeutics in the United Kingdom.
Slightly overvalued with weak fundamentals.
